Possibilities of aggressive oncosurgery in the treatment of IIA – IIIB stages of cervical cancer

Arming gynecological oncology with modern chemotherapy schemes, elements of aggressive oncosurgery, it is possible to achieve an increase in the number of cured patients with locally advanced forms of cervical cancer (CC), providing an improvement in the immediate and longterm results of treatment. The proposed method of surgical treatment is the method of choice for the surgical treatment of patients with locally advanced forms of cervical cancer (stages IIA – IIIB).

Purpose. Introduction into clinical practice of the method of surgical treatment of IIA – IIIB stages of cervical cancer.

Material and methods. Long-term results of treatment of 155 patients with morphologically verified stage IIA – IIIB cervical cancer were studied. The patients underwent neoadjuvant chemotherapy (NACT) (n=110) and chemoradiotherapy (CRT) (n=45). When resectability was achieved, the patients underwent surgical treatment using a new technique. Overall survival (OS) and progression-free survival (PFS) outcomes were assessed.

Results. In the period from 2017 to 2020, 155 patients with stage IIA – IIIB cervical cancer after NACT (n=110) and CRT (n=45) underwent combinedextended extirpation of the uterus with appendages according to our patented method. The most frequent postoperative complications were urination disorders in 106 (67 – 60.9 % and 19 – 42.2 %) patients, lymphatic cysts in 30 (20 – 18.2 % – and 10 – 22.2 %) patients and vesicovaginal fistula in 7 patients (5 – 4.6 % and 2 – 4.4 %), respectively. According to the results of a pathomorphological study, the most frequent tumor response to NACT was III degree of therapeutic pathomorphosis (TP) in 44 patients (40 %) of group 1 and in 21 patients – IV degree TP, amounting to 46.6 %. The median follow-up was 28.7 months. (from 3.6 to 51.1 months). During this time, 30 patients died in both groups (17 – 15.5 % – and 13 – 28.9 %) (p=0.047). Disease progression occurred in 16 (10.3 %) patients (6 – 5.5 % – and 10 – 22.2 %) (p = 0.004) respectively. The 3-year OS was 83.8 ± 3.7 and 71.0±6.8 (p=0.131), PFS – 93.5±2.6 and 77.7±6.6 (p=0.006).

Conclusion. The proposed method of surgical treatment of IIA – IIIB stages of cervical cancer has a novelty and can be used in practical medicine for the surgical treatment of oncology diseases in cervical cancer.

1. Moshkovich O., Lebrun-Harris L., Makaroff L. et al. Challenges and Opportunities to Improve Cervical Cancer Screening Rates in US Health Centers through Patient-Centered Medical Home Transformation. Adv. Prev. Med. 2015; 2015: 182073. doi: 10.1155/2015/182073

2. Ferlay J., Colombet M., Soerjomataram I. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer. 2019 Apr 15; 144(8):1941–1953. doi: 10.1002/ijc.31937

3. Kaprin A. D., Starinsky V. V., Petrova G. V. Malignant neoplasms in Russia in 2017 (morbidity and mortality). M., 2018. 250 p.

4. Ryeyes Santiago D. K., Khadzhimba A. S., Sobolev I. V. et al. Results of combined treatment of cervical canceruterus stages IIA–IIIB. Tumors of the female reproductive system 2018;14(4):50–5.

5. Gong Lin M. D., Zhang Jia-Wen M.D., Yin Ru-Tie M.D. et al. Safety and efficacy of neoadjuvant chemotherapy followed by radical surgery versus radical surgery alone in locally advanced cervical cancer patient. Int. J. Gynecol Cancer 2016;26(4):722–8. PMID: 26905330. DOI: 10.1097/IGC.0000000000000658.

6. Park J. Y., Kim D. Y., Kim J. H. et al. Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB 2 and IIA2 cervical cancer. J. Gynecol. Oncol. 2012;23(4):226–34. PMID: 23094125. DOI: 10.3802/jgo.2012.23.4.226

7. Katsumata N., Yoshikawa H., Kobayashi H. et al. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB 2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br. J. Cancer. 2013;108(4):1957–63. PMID: 23640393. DOI: 10.1038/bjc.2013.179

8. Landoni F., Sartori E., Maggino T. et al. Is there a role for postoperative treatment in patients with stage Ib2–IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study. Gynecol. Oncol. 2014;132(3):611–7. DOI: 10.1016/j.ygyno.2013.12.010.

9. Ovodenko D. L., Khabas G. N., Kreinina Yu.M. et al. Cervical cancer stages IB 2 – IIIB: neoadjuvant chemotherapy, radical surgery and patient survival. Siberian journal of oncology. 2021;20(3):82–89. doi: 10.21294/1814–4861–2021–20–3–82–89

10. Sao Paulo Medical Journal/RPM 112(2) Apr/May/Jun 1994.

11. Frutuoso C., Amaral N., Marques C. et al. [Wertheim-Meigs procedure. 10-year results]. Acta Med Port. 1997 Oct;10(10):631–6. Portuguese. PMID: 9477585